195 related articles for article (PubMed ID: 10071289)
1. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.
Sabbatini P; Larson SM; Kremer A; Zhang ZF; Sun M; Yeung H; Imbriaco M; Horak I; Conolly M; Ding C; Ouyang P; Kelly WK; Scher HI
J Clin Oncol; 1999 Mar; 17(3):948-57. PubMed ID: 10071289
[TBL] [Abstract][Full Text] [Related]
2. Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
Anand A; Morris MJ; Kaboteh R; Båth L; Sadik M; Gjertsson P; Lomsky M; Edenbrandt L; Minarik D; Bjartell A
J Nucl Med; 2016 Jan; 57(1):41-5. PubMed ID: 26315832
[TBL] [Abstract][Full Text] [Related]
3. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
Ulmert D; Kaboteh R; Fox JJ; Savage C; Evans MJ; Lilja H; Abrahamsson PA; Björk T; Gerdtsson A; Bjartell A; Gjertsson P; Höglund P; Lomsky M; Ohlsson M; Richter J; Sadik M; Morris MJ; Scher HI; Sjöstrand K; Yu A; Suurküla M; Edenbrandt L; Larson SM
Eur Urol; 2012 Jul; 62(1):78-84. PubMed ID: 22306323
[TBL] [Abstract][Full Text] [Related]
4. Flare phenomenon visualized by
Zhang X; Nakajima K; Mizokami A; Horikoshi H; Nishimoto K; Hashine K; Matsuyama H; Takahashi S; Wakabayashi H; Kinuya S
Ann Nucl Med; 2024 Jun; 38(6):428-440. PubMed ID: 38478154
[TBL] [Abstract][Full Text] [Related]
5. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
[TBL] [Abstract][Full Text] [Related]
6. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.
Imbriaco M; Larson SM; Yeung HW; Mawlawi OR; Erdi Y; Venkatraman ES; Scher HI
Clin Cancer Res; 1998 Jul; 4(7):1765-72. PubMed ID: 9676853
[TBL] [Abstract][Full Text] [Related]
7. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
[TBL] [Abstract][Full Text] [Related]
8. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (
Higashiyama S; Yoshida A; Kawabe J
Curr Med Imaging; 2021; 17(1):89-96. PubMed ID: 32484112
[TBL] [Abstract][Full Text] [Related]
9. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer.
Mitsui Y; Shiina H; Yamamoto Y; Haramoto M; Arichi N; Yasumoto H; Kitagaki H; Igawa M
BJU Int; 2012 Dec; 110(11 Pt B):E628-34. PubMed ID: 22788759
[TBL] [Abstract][Full Text] [Related]
10. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
[TBL] [Abstract][Full Text] [Related]
11. A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer.
Reza M; Kaboteh R; Sadik M; Bjartell A; Wollmer P; Trägårdh E
BMC Med Imaging; 2018 May; 18(1):8. PubMed ID: 29728144
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.
Meirelles GS; Schöder H; Ravizzini GC; Gönen M; Fox JJ; Humm J; Morris MJ; Scher HI; Larson SM
Clin Cancer Res; 2010 Dec; 16(24):6093-9. PubMed ID: 20975102
[TBL] [Abstract][Full Text] [Related]
13. Assessment of bone scans in advanced prostate carcinoma using fully automated and semi-automated bone scan index methods.
Takahashi Y; Yoshimura M; Suzuki K; Hashimoto T; Hirose H; Uchida K; Inoue S; Koizumi K; Tokuuye K
Ann Nucl Med; 2012 Aug; 26(7):586-93. PubMed ID: 22744807
[TBL] [Abstract][Full Text] [Related]
14. Predicting the Prognosis of Prostate Cancer Bone Metastasis Using the Bone Scan Index and Hot Spots Calculated Using VSBONEⓇ Bone Scan Index from Tc-99m-Hydroxymethylene Diphosphonate Bone Scintigraphy.
Higashiyama S; Yoshida A; Kawabe J
Urol Int; 2022; 106(9):963-969. PubMed ID: 35249033
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
BMC Cancer; 2016 Feb; 16():128. PubMed ID: 26896160
[TBL] [Abstract][Full Text] [Related]
16. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
[TBL] [Abstract][Full Text] [Related]
17. Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer.
Haupt F; Berding G; Namazian A; Wilke F; Böker A; Merseburger A; Geworski L; Kuczyk MA; Bengel FM; Peters I
Adv Ther; 2017 Apr; 34(4):986-994. PubMed ID: 28265811
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
20. Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study.
Nakajima K; Kaneko G; Takahashi S; Matsuyama H; Shiina H; Ichikawa T; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Mizokami A;
Int J Urol; 2018 May; 25(5):492-499. PubMed ID: 29633398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
